| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Molecular Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20892
Camptothecin was recently identified as an inhibitor of mammalian topoisomerase I. Similar to inhibitors of topoisomerase II, camptothecin produces DNA single-strand breaks (SSB) and DNA-protein cross-links (DPC) in mammalian cells. However, their one-to-one association, expected for trapped topoisomerase complexes, has not previously been demonstrated. We have studied camptothecin-induced SSB and DPC in Chinese hamster DC3F cells and their isolated nuclei, using the DNA alkaline elution technique. It was found that the SSB and DPC frequencies detected following camptothecin treatment depend upon the conditions used for lysis. When lysis was with sodium dodecyl sulfate, the observed frequencies of SSB and DPC were 2- to 3-fold greater than when sodium dodecyl sarkosinate (Sarkosyl) was used. In either case, the SSB:DPC ratio was close to 1. All of the camptothecin-induced SSB were protein linked, as indicated by the absence of DNA elution under nondeproteinizing conditions. DNA cleavage assays with purified topoisomerase I also indicated that the weaker Sarkosyl detergent fails to trap all of the enzyme-DNA complexes. In contrast, lysis conditions had little effect on levels of SSB or DPC produced by 4'-(9-acridinylamino)-methanesulfon-m-anisidide, suggesting that trapping of topoisomerase II complexes occurs equally well with either detergent. In experiments using isolated nuclei, it was found that the camptothecin-induced SSB, in contrast to trapped topoisomerase II complexes, can form and reverse within minutes at 4°C. The activity of camptothecin at low temperature was also seen with purified topoisomerase I. These results support the hypothesis that the SSB and DPC induced by camptothecin in mammalian cells are due to an action on topoisomerase I.
1 To whom requests for reprints should be addressed, at Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Executive Plaza North, Room 841, Bethesda, MD 20892.
Received 2/ 9/89. Accepted 6/15/89.
This article has been cited by other articles:
![]() |
J. S. Hackbarth, M. Galvez-Peralta, N. T. Dai, D. A. Loegering, K. L. Peterson, X. W. Meng, L. M. Karnitz, and S. H. Kaufmann Mitotic Phosphorylation Stimulates DNA Relaxation Activity of Human Topoisomerase I J. Biol. Chem., June 13, 2008; 283(24): 16711 - 16722. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takagi, T. S. Dexheimer, C. Redon, O. Sordet, K. Agama, G. Lavielle, A. Pierre, S. E. Bates, and Y. Pommier Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters Mol. Cancer Ther., December 1, 2007; 6(12): 3229 - 3238. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Antony, K. K. Agama, Z.-H. Miao, K. Takagi, M. H. Wright, A. I. Robles, L. Varticovski, M. Nagarajan, A. Morrell, M. Cushman, et al. Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance Cancer Res., November 1, 2007; 67(21): 10397 - 10405. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Rao, K. Agama, S. Holbeck, and Y. Pommier Batracylin (NSC 320846), a Dual Inhibitor of DNA Topoisomerases I and II Induces Histone {gamma}-H2AX as a Biomarker of DNA Damage Cancer Res., October 15, 2007; 67(20): 9971 - 9979. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Seiler, C. Conti, A. Syed, M. I. Aladjem, and Y. Pommier The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses Mol. Cell. Biol., August 15, 2007; 27(16): 5806 - 5818. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Le, M. K. Hailer, S. Buhrow, Q. Wang, K. Flatten, P. Pediaditakis, K. C. Bible, L. D. Lewis, E. A. Sausville, Y.-P. Pang, et al. Inhibition of Mitochondrial Respiration as a Source of Adaphostin-induced Reactive Oxygen Species and Cytotoxicity J. Biol. Chem., March 23, 2007; 282(12): 8860 - 8872. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-H. Miao, V. A. Rao, K. Agama, S. Antony, K. W. Kohn, and Y. Pommier 4-Nitroquinoline-1-Oxide Induces the Formation of Cellular Topoisomerase I-DNA Cleavage Complexes. Cancer Res., July 1, 2006; 66(13): 6540 - 6545. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Zamboni, L. L. Jung, M. J. Egorin, D. R. Hamburger, E. Joseph, R. Jin, S. Strychor, R. K. Ramanathan, and J. L. Eiseman Relationship between Plasma Exposure of 9-Nitrocamptothecin and Its 9-Aminocamptothecin Metabolite and Antitumor Response in Mice Bearing Human Colon Carcinoma Xenografts Clin. Cancer Res., July 1, 2005; 11(13): 4867 - 4874. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-h. Meng, G. Kohlhagen, Z.-y. Liao, S. Antony, E. Sausville, and Y. Pommier DNA-Protein Cross-links and Replication-Dependent Histone H2AX Phosphorylation Induced by Aminoflavone (NSC 686288), a Novel Anticancer Agent Active against Human Breast Cancer Cells Cancer Res., June 15, 2005; 65(12): 5337 - 5343. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Y. Liao, O. Sordet, H.-L. Zhang, G. Kohlhagen, S. Antony, W. H. Gmeiner, and Y. Pommier A Novel Polypyrimidine Antitumor Agent FdUMP[10] Induces Thymineless Death with Topoisomerase I-DNA Complexes Cancer Res., June 1, 2005; 65(11): 4844 - 4851. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Flatten, N. T. Dai, B. T. Vroman, D. Loegering, C. Erlichman, L. M. Karnitz, and S. H. Kaufmann The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons J. Biol. Chem., April 8, 2005; 280(14): 14349 - 14355. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Antony, G. Kohlhagen, K. Agama, M. Jayaraman, S. Cao, F. A. Durrani, Y. M. Rustum, M. Cushman, and Y. Pommier Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison Mol. Pharmacol., February 1, 2005; 67(2): 523 - 530. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Yu, E. Khan, M. A. Khaleque, J. Lee, G. Laco, G. Kohlhagen, S. Kharbanda, Y.-C. Cheng, Y. Pommier, and A. Bharti Phosphorylation of DNA Topoisomerase I by the c-Abl Tyrosine Kinase Confers Camptothecin Sensitivity J. Biol. Chem., December 10, 2004; 279(50): 51851 - 51861. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Zamboni, L. L. Jung, M. J. Egorin, D. M. Potter, D. M. Friedland, C. P. Belani, S. S. Agarwala, M. M. W. Wong, M. Fakih, D. L. Trump, et al. Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors Clin. Cancer Res., August 1, 2004; 10(15): 5058 - 5064. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Loegering, S. J. H. Arlander, J. Hackbarth, B. T. Vroman, P. Roos-Mattjus, K. M. Hopkins, H. B. Lieberman, L. M. Karnitz, and S. H. Kaufmann Rad9 Protects Cells from Topoisomerase Poison-induced Cell Death J. Biol. Chem., April 30, 2004; 279(18): 18641 - 18647. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chatterjee, Y. Bai, Z. Wang, S. Beach, S. Mott, R. Roy, C. Braastad, Y. Sun, A. Mukhopadhyay, B. B. Aggarwal, et al. RKIP Sensitizes Prostate and Breast Cancer Cells to Drug-induced Apoptosis J. Biol. Chem., April 23, 2004; 279(17): 17515 - 17523. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Antony, M. Jayaraman, G. Laco, G. Kohlhagen, K. W. Kohn, M. Cushman, and Y. Pommier Differential Induction of Topoisomerase I-DNA Cleavage Complexes by the Indenoisoquinoline MJ-III-65 (NSC 706744) and Camptothecin: Base Sequence Analysis and Activity against Camptothecin- Resistant Topoisomerases I Cancer Res., November 1, 2003; 63(21): 7428 - 7435. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, X. Wang, X.-Y. Zhou, D. J. Chen, G. C. Li, G. Iliakis, and Y. Wang Ku Affects the Ataxia and Rad 3-related/CHK1-dependent S Phase Checkpoint Response after Camptothecin Treatment Cancer Res., May 1, 2002; 62(9): 2483 - 2487. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Gamcsik, M. S. Kasibhatla, D. J. Adams, J. L. Flowers, O. M. Colvin, G. Manikumar, M. Wani, M. E. Wall, G. Kohlhagen, and Y. Pommier Dual Role of Glutathione in Modulating Camptothecin Activity: Depletion Potentiates Activity, but Conjugation Enhances the Stability of the Topoisomerase I-DNA Cleavage Complex Mol. Cancer Ther., November 1, 2001; 1(1): 11 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview J. Clin. Oncol., March 1, 2001; 19(5): 1501 - 1518. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Erlichman, S. A. Boerner, C. G. Hallgren, R. Spieker, X.-Y. Wang, C. D. James, G. L. Scheffer, M. Maliepaard, D. D. Ross, K. C. Bible, et al. The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux Cancer Res., January 1, 2001; 61(2): 739 - 748. [Abstract] [Full Text] |
||||
![]() |
Y. Takebayashi, F. Goldwasser, Y. Urasaki, G. Kohlhagen, and Y. Pommier Ecteinascidin 743 Induces Protein-linked DNA Breaks in Human Colon Carcinoma HCT116 Cells and Is Cytotoxic Independently of Topoisomerase I Expression Clin. Cancer Res., January 1, 2001; 7(1): 185 - 191. [Abstract] [Full Text] |
||||
![]() |
J. J. CHAMPOUX Structure-Based Analysis of the Effects of Camptothecin on the Activities of Human Topoisomerase I Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 56 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. RICH and A. V. KIRICHENKO Camptothecin Dose, Schedule, and Timing of Administration for Clinical Radiation Sensitization Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 334 - 339. [Full Text] [PDF] |
||||
![]() |
D. L. Emerson, R. Bendele, E. Brown, S. Chiang, J. P. Desjardins, L. C. Dihel, S. C. Gill, M. Hamilton, J. D. LeRay, L. Moon-McDermott, et al. Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan Clin. Cancer Res., July 1, 2000; 6(7): 2903 - 2912. [Abstract] [Full Text] |
||||
![]() |
D. Strumberg, A. A. Pilon, M. Smith, R. Hickey, L. Malkas, and Y. Pommier Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5'-Phosphorylated DNA Double-Strand Breaks by Replication Runoff Mol. Cell. Biol., June 1, 2000; 20(11): 3977 - 3987. [Abstract] [Full Text] |
||||
![]() |
T. T. Huang, S. M. Wuerzberger-Davis, B. J. Seufzer, S. D. Shumway, T. Kurama, D. A. Boothman, and S. Miyamoto NF-kappa B Activation by Camptothecin. A LINKAGE BETWEEN NUCLEAR DNA DAMAGE AND CYTOPLASMIC SIGNALING EVENTS J. Biol. Chem., March 24, 2000; 275(13): 9501 - 9509. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, C. Takimoto, R. Robey, Y. Pommier, T. Fojo, and S. E. Bates Camptothecin Resistance: Role of the ATP-binding Cassette (ABC), Mitoxantrone-resistance Half-Transporter (MXR), and Potential for Glucuronidation in MXR-expressing Cells Cancer Res., December 1, 1999; 59(23): 5938 - 5946. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Trowbridge, R. Roy, and D. T. Simmons Human Topoisomerase I Promotes Initiation of Simian Virus 40 DNA Replication In Vitro Mol. Cell. Biol., March 1, 1999; 19(3): 1686 - 1694. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Simmons, R. Roy, L. Chen, D. Gai, and P. W. Trowbridge The Activity of Topoisomerase I Is Modulated by Large T Antigen during Unwinding of the SV40 Origin J. Biol. Chem., August 7, 1998; 273(32): 20390 - 20396. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kohlhagen, K. D. Paull, M. Cushman, P. Nagafuji, and Y. Pommier Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison Mol. Pharmacol., July 1, 1998; 54(1): 50 - 58. [Abstract] [Full Text] |
||||
![]() |
S. Ohdo, T. Makinosumi, T. Ishizaki, E. Yukawa, S. Higuchi, S. Nakano, and N. Ogawa Cell Cycle-Dependent Chronotoxicity of Irinotecan Hydrochloride in Mice J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1383 - 1388. [Abstract] [Full Text] |
||||
![]() |
L. M. Martins, P. W. Mesner, T. J. Kottke, G. S. Basi, S. Sinha, J. S. Tung, P. A. Svingen, B. J. Madden, A. Takahashi, D. J. McCormick, et al. Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis Blood, December 1, 1997; 90(11): 4283 - 4296. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Valenti, W. Nieves-Neira, G. Kohlhagen, K. W. Kohn, M. E. Wall, M. C. Wani, and Y. Pommier Novel 7-Alkyl Methylenedioxy-Camptothecin Derivatives Exhibit Increased Cytotoxicity and Induce Persistent Cleavable Complexes Both with Purified Mammalian Topoisomerase I and in Human Colon Carcinoma SW620 Cells Mol. Pharmacol., July 1, 1997; 52(1): 82 - 87. [Abstract] [Full Text] |
||||
![]() |
G. C. Ireton, L. Stewart, L. H. Parker, and J. J. Champoux Expression of Human Topoisomerase I with a Partial Deletion of the Linker Region Yields Monomeric and Dimeric Enzymes That Respond Differently to Camptothecin J. Biol. Chem., August 11, 2000; 275(33): 25820 - 25830. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |